C4 Therapeutics Inc. (CCCC) News
Filter CCCC News Items
CCCC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CCCC News Highlights
- For CCCC, its 30 day story count is now at 9.
- Over the past 16 days, the trend for CCCC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CCCC are TOP and DEC.
Latest CCCC News From Around the Web
Below are the latest news stories about C4 THERAPEUTICS INC that investors may wish to consider to help them evaluate CCCC as an investment opportunity.
The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 TherapeuticsAllogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog. |
11 Hot Healthcare Stocks To Buy NowIn this article, we will be taking a look at 11 hot healthcare stocks to buy now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Hot Healthcare Stocks To Buy Now. Healthcare is a vital part of daily living for everyone, whether it be to cure […] |
Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a BetThe mean of analysts' price targets for C4 Therapeutics, Inc. (CCCC) points to a 223% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Following a 38% decline over last year, recent gains may please C4 Therapeutics, Inc. (NASDAQ:CCCC) institutional ownersKey Insights Institutions' substantial holdings in C4 Therapeutics implies that they have significant influence over the company's share price The top 9 shareholders own 51% of the company Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday and we're starting the day with a breakdown of the biggest ones worth watching! |
C4 Therapeutics (CCCC) Soars on Oncology Deal With MerckC4 Therapeutics (CCCC) inks an agreement with Merck to discover and develop degrader-antibody conjugates with a focus on one oncology target. Shares rise on the same. |
EGLE Stock Pops as Star Bulk Buys Eagle Bulk for $500 MillionEagle Bulk Shipping stock is climbing higher on Tuesday after EGLE investors learned of a merger agreement with Star Bulk Carriers. |
Why Is Aditxt (ADTX) Stock Up 58% Today?Aditxt stock is up on Tuesday as investors in ADTX shares react to the company announcing plans to acquire Evofem Biosciences. |
Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?C4 Therapeutics stock is rising higher on Tuesday as investors in CCCC shares celebrate a new collaboration agreement with Merck. |
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple MyelomaData Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity Completed Monotherapy Dose Escalation Demonstrates Anti-Myeloma Activity and Immunomodulatory Effects to Support CFT7455 in Combination with Novel Multiple Myeloma Agents and as a Monotherapy Maintenance Option CFT7455 in Combination with Dexamethasone Results in IMWG Responses at the First Two Dose Levels Studied in Multi-Refractory Multiple Myeloma Patients Do |